



World Health  
Organization



# **Standard protocol to assess the prevalence of gonorrhoea and chlamydia among pregnant women in antenatal care clinics**



**Standard protocol  
to assess the prevalence  
of gonorrhoea and  
chlamydia among  
pregnant women in  
antenatal care clinics**

## **Standard protocol to assess prevalence of gonorrhoea and chlamydia among pregnant women in antenatal care clinics**

ISBN 978-92-4-151467-5

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Standard protocol to assess prevalence of gonorrhoea and chlamydia among pregnant women in antenatal care centres. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Geneva, Switzerland

Layout by *Services Concept, Geneva*

# Acknowledgements

This document was compiled by Antonio Gerbase, Melanie Taylor (WHO Department of Reproductive Health and Research) and Monica Alonso (WHO Pan American Health Organization). Additional review, input and editing was provided by Maeve de Mello (WHO Pan American Health Organization), Eline Korenromp (Avenir Health) and Jane Rowley. Technical review and comments were provided by Takeshi Nijishima, Naoko Ishikawa and Linh Vi-Le (WHO Regional Office for the Western Pacific).

Additional technical support and input was provided by Teodora Wi, Sami Gottlieb, Igor Toskin and Nathalie Broutet (WHO Department of Reproductive Health and Research).

Additional conceptual input was provided by AnneMarie Stengaard (WHO Regional Office for Europe), Morkor Newman (WHO Regional Office for Africa) and Bharat Rewari (WHO Regional Office for South-East Asia) during an STI regional stakeholders' meeting held on 30 January–1 February 2018.

We express our gratitude to the Department for International Development (DFID), United Kingdom and the United States Centers for Disease Control and Prevention (US CDC) for their financial support, and for the technical contributions of other colleagues dedicated to strengthening STI surveillance at the country, regional and global levels.

WHO recognizes the ongoing efforts of Member States as they continue to work to improve STI surveillance and service delivery at the national level.

# Contents

<b>Acronyms and abbreviations</b>	<b>vi</b>
<b>Introduction</b>	<b>1</b>
<b>Background</b>	<b>2</b>
<b>Purpose of the protocol</b>	<b>4</b>
Objectives	4
<b>Intended use and adaptation of the protocol</b>	<b>5</b>
<b>Ethical considerations in conducting prevalence studies</b>	<b>6</b>
<b>Protocol</b>	<b>7</b>
Sampling	7
<i>Phase 1: Sampling antenatal care clinics</i>	8
<i>Approach A</i>	8
<i>Approach B</i>	9
<i>Phase 2: Sampling pregnant women attending the selected ANC clinics</i>	9
<i>Sample size determinations</i>	9
<i>Sample size determination to monitor trends in NG and CT prevalence</i>	11
<i>Eligibility criteria</i>	11
Survey implementation	12
Survey personnel and training	13
<i>Principal investigator</i>	13
<i>Survey personnel</i>	13
<i>Staff required at clinic level for data collection</i>	14
<i>Training of survey personnel</i>	15
Recruitment, counselling and consent of eligible participants	15
Data collection	16
<i>Sociodemographic data elements</i>	16

Specimen collection, transport, storage and tracking	16
<i>Collection</i>	16
<i>Transport</i>	17
<i>Storage of samples</i>	17
<i>Tracking</i>	17
Laboratory testing	17
<i>Testing options</i>	17
<i>Laboratory quality assurance</i>	18
<i>Assessing prevalence based on test performance</i>	21
Clinical care and case reporting	21
<i>Testing</i>	21
<i>Treatment</i>	22
<i>Confidential delivery of results of chlamydia and gonorrhoea testing</i>	22
<i>Case reporting to nationally notifiable disease registries</i>	22
<b>Summary</b>	<b>23</b>
<b>Bibliography</b>	<b>24</b>
Previous WHO and UNAIDS publications related to STI surveillance	24
WHO Guidelines for STI counselling and treatment of chlamydia and gonorrhoea	24
Laboratory testing guidance	25
Publications on STI trend estimation using Spectrum	25
<b>Annex 1. Example of a budget</b>	<b>26</b>
<b>Annex 2. Sample Patient consent form for prevalence survey</b>	<b>27</b>
<b>Annex 3. Sample Clinic data collection form</b>	<b>29</b>
<b>Annex 4. Sample Laboratory data collection form</b>	<b>30</b>

# Acronyms and abbreviations

<b>ANC</b>	antenatal care
<b>CI</b>	confidence interval
<b>CT</b>	<i>Chlamydia trachomatis</i>
<b>NG</b>	<i>Neisseria gonorrhoeae</i>
<b>HPV</b>	human papillomavirus
<b>NAAT</b>	nucleic acid amplification test
<b>MSM</b>	men who have sex with men
<b>NGO</b>	nongovernmental organization
<b>PCR</b>	polymerase chain reaction
<b>PPV</b>	positive predictive value
<b>SDGs</b>	Sustainable Development Goals
<b>STI</b>	sexually transmitted infection
<b>TAG</b>	technical advisory group
<b>WHO</b>	World Health Organization

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25183](https://www.yunbaogao.cn/report/index/report?reportId=5_25183)

